Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Radiotherapy for High-Risk Soft Tissue Sarcoma
NCT05602415Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Nov 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in soft tissue sarcoma (STS), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05602415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602415.